Clinical Pharmacology & Therapeutics最新文献

筛选
英文 中文
Do Brain Extracellular Fluid Concentrations Predict PET-Inferred Receptor Occupancy in Human CNS? A Mechanistic Model-Based Analysis of Dopamine D2 Receptor Ligands. 脑细胞外液浓度能预测pet推断的受体在人中枢神经系统中的占据吗?多巴胺D2受体配体的机制模型分析。
IF 4.9 2区 医学
Clinical Pharmacology & Therapeutics Pub Date : 2026-11-01 Epub Date: 2026-08-25 DOI: 10.1002/cpt.70453
Divakar Budda, J G Coen van Hasselt, Elizabeth C M de Lange
{"title":"Do Brain Extracellular Fluid Concentrations Predict PET-Inferred Receptor Occupancy in Human CNS? A Mechanistic Model-Based Analysis of Dopamine D2 Receptor Ligands.","authors":"Divakar Budda, J G Coen van Hasselt, Elizabeth C M de Lange","doi":"10.1002/cpt.70453","DOIUrl":"10.1002/cpt.70453","url":null,"abstract":"<p><p>We previously developed a mechanistic model framework integrating physiologically based pharmacokinetic model (LeiCNS-PK3.0), binding kinetics, and receptor dynamics, to predict regional human central nervous system (CNS) receptor occupancy (RO), using brain extracellular fluid (brain<sub>ECF</sub>) concentrations. Positron emission tomography (PET)-RO is a non-invasive biomarker to estimate, and validate human CNS RO. However, for highly lipophilic drug buprenorphine brain<sub>ECF</sub> concentrations-based RO predictions deviated substantially from PET-RO. This mismatch and the lipophilicity driven brain cell membrane (brain<sub>M</sub>) accumulation motivated us to investigate relevance of brain<sub>ECF</sub> vs. brain<sub>M</sub> concentrations for PET-RO. We identified human studies reporting plasma PK and CNS PET-RO for D2 receptor ligands spanning lipophilicities. Population PK parameters, derived via model fitting, served as inputs to the mechanistic framework to simulate brain<sub>ECF</sub> and brain<sub>M</sub>-based regional RO and compared with PET-RO. We systematically assessed the impact of lipophilicity, receptor dynamics, endogenous ligands, and schizophrenia-related physiological changes on simulations accuracy. Brain<sub>M</sub> concentrations showed better agreement with PET-RO than brain<sub>ECF</sub> for five of eight D2 ligands. However, neither improvement nor brain<sub>M</sub> partitioning showed a clear trend with logP; <math> <mrow><msubsup><mi>K</mi> <mi>p</mi> <mi>M</mi></msubsup> </mrow> </math> substitution yielded modest improvement. Receptor internalization reduced simulated RO and enhanced PET agreement (remoxipride/haloperidol), independent of lipophilicity. Endogenous dopamine and schizophrenia-related changes had negligible effects. This study demonstrated that brain<sub>M</sub> concentrations offer improved PET-RO alignment for a subset of compounds, independent of lipophilicity suggesting role of other drug-specific factors in brain<sub>M</sub> accumulation or lack thereof. The integrated mechanistic framework offers potential to enhance CNS drug treatment, subject to further development via qMRI, hMRI, MRS, and controlled clinical studies.</p>","PeriodicalId":153,"journal":{"name":"Clinical Pharmacology & Therapeutics","volume":" ","pages":"1389-1401"},"PeriodicalIF":4.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13506964/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148816784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Physiologically Based Pharmacokinetic Modeling to Assess Transporter-Mediated Drug-Drug Interactions in Support of Labeling Recommendations for Zavegepant Nasal Spray. 基于生理的药代动力学模型评估转运体介导的药物-药物相互作用,支持zavegegpant鼻喷雾剂的标签推荐。
IF 4.9 2区 医学
Clinical Pharmacology & Therapeutics Pub Date : 2026-11-01 Epub Date: 2026-09-04 DOI: 10.1002/cpt.70460
Alice Ke, Ernesto Callegari, Manthena V S Varma, Mayur K Ladumor, Chieko Muto, Richard J Bertz, Hannah M Jones, Vaishali Sahasrabudhe, Jing Liu
{"title":"Physiologically Based Pharmacokinetic Modeling to Assess Transporter-Mediated Drug-Drug Interactions in Support of Labeling Recommendations for Zavegepant Nasal Spray.","authors":"Alice Ke, Ernesto Callegari, Manthena V S Varma, Mayur K Ladumor, Chieko Muto, Richard J Bertz, Hannah M Jones, Vaishali Sahasrabudhe, Jing Liu","doi":"10.1002/cpt.70460","DOIUrl":"10.1002/cpt.70460","url":null,"abstract":"<p><p>Zavegepant nasal spray, a calcitonin gene-related peptide receptor antagonist indicated for acute treatment of migraine with or without aura in adults, is a substrate for organic anion transporting polypeptide 1B3 (OATP1B3), Na<sup>+</sup>/taurocholate cotransporting polypeptide (NTCP), P-glycoprotein (P-gp), and cytochrome P450 3A4 (CYP3A4). In clinical drug-drug interaction (DDI) studies, oral zavegepant exposure increased in the presence of multiple-dose (MD) rifampin or itraconazole; however, no interaction was observed between intranasal (IN) zavegepant and itraconazole. A physiologically based pharmacokinetic (PBPK) model was developed and validated using in vitro, human mass balance, and observed clinical zavegepant pharmacokinetic data and was employed to assess clinical DDI mechanisms and further support zavegepant nasal spray labeling recommendations. PBPK modeling indicated that DDI observed between itraconazole and oral zavegepant is primarily driven by intestinal P-gp inhibition, and observed DDI with MD rifampin primarily results from hepatic uptake inhibition. Modeling predicted an increase in plasma exposure (AUC ratio [AUCR] = 2.39) of IN zavegepant with single-dose (SD) rifampin; IN zavegepant plasma exposure was also predicted to increase with MD rifampin (AUCR = 2.11). Predicted IN zavegepant exposure change with SD cyclosporine A was 1.58-fold (AUCR) when assuming 90:10 proportion for OATP1B3:NTCP contribution to hepatic uptake. CYP3A inducers, carbamazepine and efavirenz, were predicted to have minimal effect on IN zavegepant PK. Overall, PBPK modeling and observed PK data support that CYP3A/P-gp inhibitors and inducers do not produce clinically relevant modulation in IN zavegepant plasma exposure; however, OATP1B3/NTCP inhibitors can significantly increase IN zavegepant exposure, and coadministration should be avoided.</p>","PeriodicalId":153,"journal":{"name":"Clinical Pharmacology & Therapeutics","volume":" ","pages":"1402-1413"},"PeriodicalIF":4.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13545016/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148890566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advancing Evidence Generation in Small, Diverse, Understudied Population. 在小型、多样化、未充分研究的人群中推进证据生成。
IF 4.9 2区 医学
Clinical Pharmacology & Therapeutics Pub Date : 2026-10-31 DOI: 10.1002/cpt.70548
Amitava Mitra, Anne-Gaelle Dosne, Douglas Steinbach, Hannah M Jones, John Mondick, Rajesh Krishna
{"title":"Advancing Evidence Generation in Small, Diverse, Understudied Population.","authors":"Amitava Mitra, Anne-Gaelle Dosne, Douglas Steinbach, Hannah M Jones, John Mondick, Rajesh Krishna","doi":"10.1002/cpt.70548","DOIUrl":"https://doi.org/10.1002/cpt.70548","url":null,"abstract":"<p><p>Many clinically important patient groups remain systematically underrepresented in drug development. Among these are patients with severe or time-varying organ dysfunction, pregnant and lactating women, children with ultrarare diseases, and people from socioeconomically or geographically underserved communities. Traditional clinical trials frequently exclude such groups. Little direct evidence is generated as a result, leaving benefit-risk and dosing decisions uncertain and trial findings poorly generalizable to the patients who will ultimately receive the drug. No single method closes this gap. This review argues that progress instead comes from integration, combining model-informed drug development, registries and real-world data, external and virtual controls, Bayesian borrowing, and patient-centric trial designs into a coherent totality-of-evidence package. These tools are maturing from a role that supplements clinical data toward one that can, in defined settings, partially replace it. The appropriate approach may differ by population. For example, (1) mechanistic modeling and exposure prediction for organ replacement therapy/changing organ function or from the altered maternal-fetal-infant physiology that makes prospective studies impractical; (2) registry-based external controls and natural history data where patients are too few to randomize; and (3) decentralized, partnership-driven designs to reach populations that structural barriers would otherwise exclude. Three case studies (dose justification across hepatic and renal impairment, evidence generation in women of childbearing potential with chronic autoimmune disease, and a registry-anchored ultrarare pediatric program) illustrated these approaches. Mapped to evolving regulatory frameworks, these strategies can deliver population-appropriate dosing at approval rather than through postmarketing commitments, accelerating equitable access to safe and effective therapies.</p>","PeriodicalId":153,"journal":{"name":"Clinical Pharmacology & Therapeutics","volume":" ","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13723151/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149316455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From Information to Insight: A Decision Architecture for Informed Governance. 从信息到洞察:知情治理的决策体系结构。
IF 4.9 2区 医学
Clinical Pharmacology & Therapeutics Pub Date : 2026-10-30 DOI: 10.1002/cpt.70539
Jack A Cook
{"title":"From Information to Insight: A Decision Architecture for Informed Governance.","authors":"Jack A Cook","doi":"10.1002/cpt.70539","DOIUrl":"10.1002/cpt.70539","url":null,"abstract":"","PeriodicalId":153,"journal":{"name":"Clinical Pharmacology & Therapeutics","volume":" ","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13721024/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149293544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patients with Chronic Inflammatory Diseases Can Experience Higher Exposure of Small Molecule Drugs than Healthy Volunteers: An Analysis of Recently Approved Drugs. 慢性炎症性疾病患者可能比健康志愿者有更高的小分子药物暴露:最近批准的药物分析
IF 4.9 2区 医学
Clinical Pharmacology & Therapeutics Pub Date : 2026-10-29 DOI: 10.1002/cpt.70535
Johannes Tillil, Sathej Gopalakrishnan, Jennifer Dong, Karthik Venkatakrishnan, Charlotte Kloft, Wilhelm Huisinga, Lena Klopp-Schulze
{"title":"Patients with Chronic Inflammatory Diseases Can Experience Higher Exposure of Small Molecule Drugs than Healthy Volunteers: An Analysis of Recently Approved Drugs.","authors":"Johannes Tillil, Sathej Gopalakrishnan, Jennifer Dong, Karthik Venkatakrishnan, Charlotte Kloft, Wilhelm Huisinga, Lena Klopp-Schulze","doi":"10.1002/cpt.70535","DOIUrl":"10.1002/cpt.70535","url":null,"abstract":"<p><p>Chronic inflammation has long been known to downregulate the activity of certain cytochrome P450 (CYP) enzymes-the main enzymes responsible for the phase I metabolism of many small molecule drugs-potentially leading to higher exposures in patients with chronic inflammatory diseases compared to healthy volunteers. Neglecting this potential difference in the pharmacokinetics can have several implications for dose translation from healthy volunteers to proof of concept studies in patients: sub-optimal design of dose-ranging studies and increased risk of adverse events due to overprediction of safety margins. Yet this disease-drug interaction has rarely been prospectively considered in drug development in the past. This review aims to quantify the extent of decreased (apparent) clearance in patients compared to healthy volunteers of small molecule drugs that were approved by the FDA in the past 15 years for important chronic inflammatory indications. Based on reported population pharmacokinetic analyses, 25% (5 of 20) of small molecule drugs approved for the selected indications showed a meaningfully higher area under the curve (AUC) by more than 25% in patients compared to healthy volunteers. As a common feature, all five drugs are primarily metabolized by CYP3A4 or CYP2C19 and for four of the five drugs, the contribution of metabolism to their elimination is more than 50%. These findings highlight the need to assess a drug's susceptibility to changes in the metabolic activity under chronic inflammation when translating dose predictions from healthy volunteers to patients.</p>","PeriodicalId":153,"journal":{"name":"Clinical Pharmacology & Therapeutics","volume":" ","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13719661/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149293528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating the Association Between PPI Use and Dementia Risk Considering Methodological Choices: An Updated Meta-Analysis. 考虑方法选择评估PPI使用与痴呆风险之间的关系:一项更新的荟萃分析。
IF 4.9 2区 医学
Clinical Pharmacology & Therapeutics Pub Date : 2026-10-28 DOI: 10.1002/cpt.70534
Heonyoung Ha, Hyun Woo Lee, Jae-Eun Park, Byoung Seok Ye, Yun Mi Yu, Young-Mi Ah
{"title":"Evaluating the Association Between PPI Use and Dementia Risk Considering Methodological Choices: An Updated Meta-Analysis.","authors":"Heonyoung Ha, Hyun Woo Lee, Jae-Eun Park, Byoung Seok Ye, Yun Mi Yu, Young-Mi Ah","doi":"10.1002/cpt.70534","DOIUrl":"10.1002/cpt.70534","url":null,"abstract":"<p><p>Proton pump inhibitors (PPIs), commonly prescribed for gastrointestinal disorders, have been investigated for their association with the risk of dementia. We aimed to assess the association between PPI use and dementia risk in older adults and examine the influence of methodological choices on this association. We conducted a meta-analysis of longitudinal observational studies, including subgroup analyses to address time-related biases and comparator selection. Relevant studies were systematically searched in the MEDLINE, Embase, and CENTRAL databases from their inception to January 25, 2026. Twenty-three studies of older adults without dementia at baseline, reporting adjusted estimates for PPI users versus a comparator group, met the inclusion criteria. The pooled hazard ratio (HR) indicated a modest association between PPI use and dementia (HR = 1.18, 95% confidence interval [CI] 1.02-1.37). Dementia risk did not differ significantly between PPI users and users of histamine-2 receptor antagonists (H2RAs) (HR = 1.04, 95% CI 0.89-1.20). In a post hoc analysis, H2RA use itself was associated with dementia (HR = 1.44, 95% CI 1.07-1.93), whereas excluding H2RA-treated patients strengthened the PPI estimate (HR = 1.75, 95% CI 1.38-2.22). Estimates also differed according to how time-related bias was handled: lag time, HR = 1.25, 95% CI 1.07-1.46; time-varying exposure, HR = 1.38, 95% CI 1.16-1.64. PPI use was modestly associated with incident dementia. However, the strength and specificity depended substantially on comparator selection and handling of time-related bias. Well-designed, long-term studies using active comparators are needed to clarify whether this effect is PPI-specific.</p>","PeriodicalId":153,"journal":{"name":"Clinical Pharmacology & Therapeutics","volume":" ","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13716873/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149284310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biosimilar Development Considerations for Therapeutic Proteins With Limited Systemic Exposure: A Landscape Analysis and Pathway Evaluation. 有限系统暴露的治疗性蛋白的生物仿制药开发考虑:景观分析和途径评估。
IF 4.9 2区 医学
Clinical Pharmacology & Therapeutics Pub Date : 2026-10-27 DOI: 10.1002/cpt.70543
Ting Wang, Jenny Zheng, Po-Hung Hsieh, Anh-Dung Le, Yow-Ming Wang, Qin Sun
{"title":"Biosimilar Development Considerations for Therapeutic Proteins With Limited Systemic Exposure: A Landscape Analysis and Pathway Evaluation.","authors":"Ting Wang, Jenny Zheng, Po-Hung Hsieh, Anh-Dung Le, Yow-Ming Wang, Qin Sun","doi":"10.1002/cpt.70543","DOIUrl":"10.1002/cpt.70543","url":null,"abstract":"<p><p>Biosimilar development for therapeutic proteins (TPs) with limited systemic exposure presents distinct challenges, as the new paradigm based on comparative analytical assessments plus pharmacokinetic similarity without a comparative efficacy study (CES) is inapplicable. Of 19 TPs with limited systemic exposure, 15 are well-characterized, of which 12 have at least one CES-feasible indication. The remaining 3 may require alternative strategies, including pharmacodynamic (PD) biomarker approaches or optimized CES designs, underscoring the need for proactive regulatory engagement.</p>","PeriodicalId":153,"journal":{"name":"Clinical Pharmacology & Therapeutics","volume":" ","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13713891/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149284256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Use of SGLT2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors in Incident Hyponatremia in Patients with Type 2 Diabetes: Multicenter Target Trial Emulations. SGLT2抑制剂、GLP-1受体激动剂和DPP-4抑制剂在2型糖尿病患者低钠血症中的应用:多中心靶点试验模拟
IF 4.9 2区 医学
Clinical Pharmacology & Therapeutics Pub Date : 2026-10-26 DOI: 10.1002/cpt.70536
Ying-Hsuan Lin, Daniel Hsiang-Te Tsai, Miyuki Hsing-Chun Hsieh, Chia-Chun Lee, Chin-Chung Tseng, Ming-Cheng Wang, Edward Chia-Cheng Lai, Kuan-Hung Liu
{"title":"Use of SGLT2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors in Incident Hyponatremia in Patients with Type 2 Diabetes: Multicenter Target Trial Emulations.","authors":"Ying-Hsuan Lin, Daniel Hsiang-Te Tsai, Miyuki Hsing-Chun Hsieh, Chia-Chun Lee, Chin-Chung Tseng, Ming-Cheng Wang, Edward Chia-Cheng Lai, Kuan-Hung Liu","doi":"10.1002/cpt.70536","DOIUrl":"10.1002/cpt.70536","url":null,"abstract":"<p><p>Hyponatremia poses risks in type 2 diabetes, yet comparative electrolyte safety across glucose-lowering therapies remains unclear. We evaluated the risk of incident hyponatremia associated with sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and dipeptidyl peptidase-4 (DPP-4) inhibitors in real-world practice. Using electronic health records from 155 healthcare organizations in the TriNetX Global Collaborative Network, we conducted multicenter active-comparator, new-user target trial emulations with 1:1 propensity score matching. For each pairwise comparison, adults with type 2 diabetes initiating either drug class, with no record of either class during the preceding 365 days, were included. The primary outcome was incident hyponatremia (ICD-10-CM E87.1 or serum sodium ≤ 135 mmol/L); sensitivity outcomes included diagnosis-only, laboratory-only, and stricter laboratory thresholds. Among more than 300,000 matched pairs per comparison, SGLT2 inhibitors and GLP-1 RAs were each associated with a 15% lower hazard of hyponatremia than DPP-4 inhibitors (hazard ratio [HR], 0.850; 95% confidence interval [CI], 0.842-0.858 and HR, 0.847; 95% CI: 0.838-0.856). The lower risk persisted at stricter sodium thresholds and across clinically relevant subgroups, including patients with heart failure, chronic kidney disease, or high-risk medications use. SGLT2 inhibitors and GLP-1 RAs were broadly comparable (HR, 0.962; 95% CI: 0.952-0.971). Positive and negative control outcomes were consistent with expectations. Overall, SGLT2 inhibitors and GLP-1 RAs were associated with a lower risk of incident hyponatremia than DPP-4 inhibitors. These real-world findings provide reassurance regarding the electrolyte safety of SGLT2 inhibitors and GLP-1 RAs, complementing their established cardiorenal benefits.</p>","PeriodicalId":153,"journal":{"name":"Clinical Pharmacology & Therapeutics","volume":" ","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13710830/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149259928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The EMA Qualification Opinion for CYP Inhibition-Mediated Drug-Drug Interaction Predictions: Implications for PBPK Credibility Assessment in the Era of ICH M15. CYP抑制介导的药物相互作用预测的EMA鉴定意见:ICH M15时代PBPK可信度评估的意义
IF 4.9 2区 医学
Clinical Pharmacology & Therapeutics Pub Date : 2026-10-26 DOI: 10.1002/cpt.70533
Karen Rowland Yeo, Sibylle Neuhoff, Oliver Hatley, Iain Gardner, Céline Brochot, Frédéric Y Bois, Masoud Jamei
{"title":"The EMA Qualification Opinion for CYP Inhibition-Mediated Drug-Drug Interaction Predictions: Implications for PBPK Credibility Assessment in the Era of ICH M15.","authors":"Karen Rowland Yeo, Sibylle Neuhoff, Oliver Hatley, Iain Gardner, Céline Brochot, Frédéric Y Bois, Masoud Jamei","doi":"10.1002/cpt.70533","DOIUrl":"10.1002/cpt.70533","url":null,"abstract":"<p><p>Clinical pharmacology and pharmacometrics teams are now being encouraged to implement the ICH M15 framework in drug development to support model-informed decisions in regulatory submissions. Although model performance is an important component of model evaluation, regulatory confidence also depends on the intended context of use (CoU) and the supporting level of evidence. This is particularly relevant for physiologically based pharmacokinetic (PBPK) modeling, where increasing regulatory application has strengthened the need for structured approaches to evaluate predictive performance, extrapolation, uncertainty, and model applicability. The Simcyp Simulator (V19R1) was recently qualified by the EMA for prediction of CYP-mediated drug-drug interactions (DDIs) involving six enzymes (CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4/5), competitive inhibition, and mechanism-based inhibition for both victim and perpetrator drugs across three CoUs. Qualification data demonstrated consistent predictive performance across the three CoUs, with average fold errors close to unity, absolute average fold errors ranging from 1.23 to 1.25, and 98.8% of 246 predictions falling within 2-fold of observed values. The opinion predates ICH M15; however, it does not provide either a mapping to its credibility concepts or an operational basis for extending platform-level evidence to a specific investigational drug. We address this gap with an explicit mapping of the qualification opinion onto ICH M15 credibility concepts and an integrated approach linking qualification evidence, drug-specific validation, predictive performance, uncertainty characterization, and prospective application, illustrating how confidence in PBPK-supported regulatory decisions can be established within an ICH M15-aligned framework.</p>","PeriodicalId":153,"journal":{"name":"Clinical Pharmacology & Therapeutics","volume":" ","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13710410/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149259961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advancing Therapeutics for Children with Medical Complexity: The Role of Model-Informed Precision Dosing and Genotype-Stratified Trials. 推进治疗儿童的医疗复杂性:模型知情的精确剂量和基因型分层试验的作用。
IF 4.9 2区 医学
Clinical Pharmacology & Therapeutics Pub Date : 2026-10-26 DOI: 10.1002/cpt.70532
Rose Gelineau-Morel, J Steven Leeder, Jonathan B Wagner
{"title":"Advancing Therapeutics for Children with Medical Complexity: The Role of Model-Informed Precision Dosing and Genotype-Stratified Trials.","authors":"Rose Gelineau-Morel, J Steven Leeder, Jonathan B Wagner","doi":"10.1002/cpt.70532","DOIUrl":"10.1002/cpt.70532","url":null,"abstract":"<p><p>Model-informed drug development (MIDD) and model-informed precision dosing (MIPD) increasingly guide drug development, regulatory decision-making, and individualized therapy but rely on robust data. Current models inadequately represent children with medical complexity (CMC), whose unique physiology, comorbidities, and polypharmacy contribute to substantial variability in drug exposure and response. We propose a framework using genotype-stratified trials to characterize pharmacogenetic sources of variability, informing MIDD and MPID models while helping identify additional determinants of therapeutic response in CMC.</p>","PeriodicalId":153,"journal":{"name":"Clinical Pharmacology & Therapeutics","volume":" ","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13698882/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149259898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书